Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models

BACKGROUND: Renal cell carcinoma (RCC) is among the most common malignant cancers of males worldwide. For advanced RCC patients, there still is no effective therapy. Immune checkpoint blockade therapies have shown benefits for many cancers, but previous clinical trials of immune checkpoint blockade...

Descripción completa

Detalles Bibliográficos
Autor principal: Cui, Shujin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Animal Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516681/
https://www.ncbi.nlm.nih.gov/pubmed/28697172
http://dx.doi.org/10.12659/MSM.902426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516681/
https://www.ncbi.nlm.nih.gov/pubmed/28697172
http://dx.doi.org/10.12659/MSM.902426

Ejemplares similares